Viridian Therapeutics, Inc.\DE (VRDN) Net Cash Flow (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Net Cash Flow history runs 14 years deep, the most recent figure standing at -$36.0 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 316.81% year-over-year to -$36.0 million; the TTM figure through Mar 2026 stood at $60.1 million (up 144.69% YoY), while the FY2025 annual figure was $112.8 million, up 3588.65% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$36.0 million, down from $42.7 million in the prior quarter.
• The five-year high for Net Cash Flow was $312.9 million in Q3 2022, with the low at -$188.6 million in Q4 2022.
• The 5-year median for Net Cash Flow is $435000.0 (2022), against an average of $7.9 million.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow slumped 2032.6% in 2022, then soared 1218.35% in 2024.
• Viridian Therapeutics, Inc.\DE's Net Cash Flow stood at -$188.6 million in 2022, then jumped by 95.35% to -$8.8 million in 2023, then slumped by 1048.49% to -$100.7 million in 2024, then surged by 142.43% to $42.7 million in 2025, then tumbled by 184.32% to -$36.0 million in 2026.
• Business Quant data shows VRDN's Net Cash Flow at -$36.0 million in Q1 2026, $42.7 million in Q4 2025, and $52.3 million in Q3 2025.